Somryst® is the first and only prescription digital therapeutic indicated to treat chronic insomnia. Somryst is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia – CBT-I) to adults 22 years of age and older with chronic insomnia.

NightWare develops an application on an Apple Watch that aims to help people suffering from nightmares. The company offers wearable technology that learns sleep patterns and customizes a treatment for each individual. NightWare was founded in 2015 and is based in Hopkins, Minnesota.

Somryst provides a clinician facing dashboard that allows healthcare providers to track patient treatment and progress. The clinician dashboard displays information about patients’ use of Somryst, including the Insomnia Severity Index (ISI)1, the Patient Health Questionnaire 8 (PHQ-8)2 scores, and sleep metrics derived from nightly sleep diaries.

 NightWare is constantly capturing data and adapting to the patient’s evolving sleep patterns. Our prescription digital therapeutic platform creates a customized intervention based on the ongoing accumulation of data from the user. The more you use NightWare, the smarter it gets. Leading to increased use generates better learnings.